Please assess the completion status of the following clinical trial:

Trial Title: Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 months to 85 years.~* Able to complete the informed consent process or, if a minor, a parent or guardian who is able to complete the informed consent process; an assent form also will be completed for children age 7 and older.~* Willing and able to complete the study protocol, study-related activities, and visits.~* Diagnosis of uncomplicated skin and soft tissue infection (uSSTI), either cellulitis (defined as an inflammation of skin and associated skin structures) or abscess (defined as a circumscribed collection of pus), evidenced by at least 2 of the following localized signs or symptoms on the skin for at least 24 hours:~  1. Erythema~ 2. Swelling or induration~ 3. Local warmth~ 4. Purulent drainage~ 5. Tenderness to palpation or pain~* Able to take oral antibiotic therapy, either in pill or suspension form.~Exclusion Criteria:~* Hospital in-patient.~* Hospitalization within the prior 14 days.~* Residence in a long-term skilled nursing facility.~* Requirement for hospitalization for skin infection or other condition.~* Previous enrollment in this protocol.~* Participation in another clinical trial within the previous 30 days.~* Superficial skin infection only, including:~  1. Impetigo~ 2. Ecthyma~ 3. Folliculitis~ 4. Infections that have a high cure rate after surgical incision alone (such as isolated furunculosis) or after topical or local measures~* Unstable psychiatric or psychological condition rendering the subject unlikely to be cooperative or to complete study requirements.~* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with the adherence or subject compliance with study requirements.~* Systolic blood pressure \> 180 mm Hg.~* Systolic blood pressure (SBP) less than an age-specific critical value:~  1. Age 6 - 11 months: \< 70 mm Hg~ 2. Age 1 to 8 years: \< 80 mm Hg~ 3. Age 9 to 17 years: \< 90 mm Hg~ 4. Age greater than or equal to 18 years: \< 90 mm Hg~* Heart rate less than 45 beats per minute (BPM).~* Heart rate greater than an age-specific critical value:~  1. Age 6 - 11 months: \> 140 BPM~ 2. Age 1 to 8 years: \> 120 BPM~ 3. Age 9 to 17 years: \> 120 BPM~ 4. Age greater than or equal to 18 years: \> 120 BPM.~* Oral temperature (or equivalent rectal, tympanic membrane, axillary) less than 35.5 degrees Celsius (95.9 degrees Fahrenheit).~* Oral temperature (or equivalent rectal, tympanic membrane, axillary) greater than age-specific critical value:~  1. Age 6 - 11 months: \> 38.0 degrees Celsius (100.4 degrees Fahrenheit)~ 2. Age 1 to 8 years: \> 38.5 degrees Celsius (101.3 degrees Fahrenheit)~ 3. Age 9 to 17 years: \> 38.5 degrees Celsius (101.3 degrees Fahrenheit)~ 4. Age greater than or equal to 18 years: \> 38.5 degrees Celsius (101.3 degrees Fahrenheit).~* Documented human or witnessed animal bite in the past 30 days at the site of infection.~* Systemic antibacterial therapy with antistaphylococcal activity within the prior 14 days.~* The following concomitant medications: warfarin, phenytoin, methotrexate, rosiglitazone or sulfonylureas and systemically administered antibacterial agents with activity against staphylococci.~* Diagnosed or suspected disseminated or severe Staphylococcus aureus or group A streptococcal (GAS) infection, including lymphangitic spread of skin infection, septicemia, bacteremia, pneumonia, endocarditis, osteomyelitis, septic arthritis, gangrene, necrotizing fasciitis, myositis, or other serious infections.~* Infection at an anatomical skin site requiring specialized management or specialized antimicrobial therapy, including:~  1. Periauricular or orbital infection~ 2. Perirectal infection~ 3. Suspected deep space infection of the hand or foot~ 4. Genital infection~ 5. Mastitis~ 6. Bursitis~* Radiographic evidence or suspicion of gas in the tissue or foreign body infection (note: radiography is not required for screening and can be performed at the discretion of the treating physician).~* Gastrointestinal symptoms such as nausea, vomiting, or diarrhea of a severity that would preclude consumption of oral antibiotics.~* Hypersensitivity or history of allergic reaction to study drug.~* History of glucose-6-phosphate dehydrogenase (G6PD) deficiency.~* Third trimester pregnancy: pregnant women must have gestational age estimated by an objective means, e.g. ultrasound, fundal height, and women who are within 4 weeks of the third trimester of pregnancy, defined as week 27 of pregnancy, are not eligible.~* Currently breast feeding.~* Severe or morbid obesity with a body mass index (BMI) \>40 kg/m\^2.~* Complicated skin or soft tissue infection, such as:~  1. Catheter or catheter site infection within 30 days of placement~ 2. Surgical site infection~ 3. Known or suspected prosthetic device infection~ 4. Suspected Gram-negative or anaerobic pathogen~ 5. Unusual exposure history (e.g., underwater injury, fish-tank exposure, heavy soil exposure, etc)~ 6. Infection at the site of an area of underlying skin disease such as chronic eczema, psoriasis, atopic dermatitis, or chronic venous stasis~* History of underlying immunocompromising condition or immunodeficiency, for example:~  1. Diabetes mellitus~ 2. Chronic renal failure, creatinine clearance \<30 ml/min~ 3. Renal dialysis within the past 180 days~ 4. Human immunodeficiency virus (HIV)-positive with either cluster of differentiation (CD)4 count \<200 or \<4 percent CD4 in the past 180 days or HIV-positive and no documented CD4 count in the past 4 months~ 5. Organ or bone marrow transplantation (ever), immunosuppressive therapy within the past 180 days, severe liver disease~ 6. Other serious underlying disease, as determined by the treating physician or the investigator

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Limited Abscess (Type: EXPERIMENTAL): Limited abscess with or without cellulitis less than or equal to 5 cm in diameter will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA 300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children; or c) placebo two capsules three times daily.
- Cellulitis or Larger Abscess (Type: EXPERIMENTAL): Subjects with cellulitis only or abscess \> 5 cm in diameter, or with 2 or more sites of skin infection will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete